Daily Market Updates: AstraZeneca COPD drug gets two late-stage trial wins with full data

Earnings

Home›Earnings›Previews›AstraZeneca COPD drug gets two late-stage trial wins w…

AstraZeneca COPD drug gets two late-stage trial wins with full data

The company’s peak annual sales forecast points to more than $5 billion if the therapy meets expectations.

Reported · Written up by our desk · Previews

AstraZeneca has received full data from two late-stage trials of its chronic obstructive pulmonary disease, or COPD, drug, with results described as two additional late-stage wins, according to CNBC Markets and CNBC World.

The updated full dataset reinforces hopes the treatment could become a breakthrough COPD option, setting up the potential to contribute to AstraZeneca’s peak annual sales forecast of more than $5 billion.

CNBC Markets and CNBC World said the latest trial wins support the company’s blockbuster hopes as the therapy advances on the late-stage track.

← Newer storyUS feed industry cites $267.1B footprint and 80,300 jobs Older story →Morgan Stanley flags improving earnings outlook for AI adopters

More like this

EarningsNVIDIA shares hit record highs as price targets rise toward Q3

EarningsEmerson and Rockwell Automation seen benefiting from manufacturing PMI jump

EarningsAmazon locks in $1 billion-plus Synopsys deal to expand custom chips

EarningsNVIDIA expands buyback authorization by $150 billion to $235 billion

EarningsSmall-caps highlight Ascentage Pharma, Maze Therapeutics, Pagaya catalysts

Sources

CNBC MarketsAstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

CNBC WorldAstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

Earnings

AstraZeneca COPD drug gets two late-stage trial wins with full data

More like this

Sources

Get the close, explained.